Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.

@article{Nilsson2016PatientreportedQA,
  title={Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.},
  author={S Nilsson and Paul R Cislo and Oliver A Sartor and Nicholas John Vogelzang and R E Coleman and J M O'Sullivan and Jonathan D. Reuning-Scherer and M Shan and L Zhan and C Parker},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2016},
  volume={27 5},
  pages={868-74}
}
BACKGROUND Radium-223 dichloride (radium-223), a first-in-class α-emitting radiopharmaceutical, is recommended in both pre- and post-docetaxel settings in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases based on overall survival benefit demonstrated in the phase III ALSYMPCA study. ALSYMPCA included prospective measurements of health-related quality of life (QOL) using two validated instruments: the general EuroQoL 5D (EQ-5D) and the disease-specific… CONTINUE READING

From This Paper

Figures and tables from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Efficacy and safety of radium-223 dichloride by baseline opioid use in patients with castration-resistant prostate cancer and symptomatic bone metastases: results from ALSYMPCA

  • D Bottomley, N Vogelzang, R Coleman
  • Presentation at: Global Congress on Prostate…
  • 2015
1 Excerpt

Patient-reported quality of life analysis of radium-223 dichloride evaluating pain relief from the phase 3 ALSYMPCA study

  • S Nilsson, M Tomblyn, P Cislo
  • J Clin Oncol
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…